Overview

Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Bicara Therapeutics

Treatments:

Pembrolizumab